These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18347343)

  • 21. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
    Leoni F; Zaliani A; Bertolini G; Porro G; Pagani P; Pozzi P; Donà G; Fossati G; Sozzani S; Azam T; Bufler P; Fantuzzi G; Goncharov I; Kim SH; Pomerantz BJ; Reznikov LL; Siegmund B; Dinarello CA; Mascagni P
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2995-3000. PubMed ID: 11867742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
    Luznik L; Jalla S; Engstrom LW; Iannone R; Fuchs EJ
    Blood; 2001 Dec; 98(12):3456-64. PubMed ID: 11719388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
    Choi SW; Braun T; Henig I; Gatza E; Magenau J; Parkin B; Pawarode A; Riwes M; Yanik G; Dinarello CA; Reddy P
    Blood; 2017 Oct; 130(15):1760-1767. PubMed ID: 28784598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients.
    He W; Racine JJ; Johnston HF; Li X; Li N; Cassady K; Liu C; Deng R; Martin P; Forman S; Zeng D
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):920-8. PubMed ID: 24691220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
    Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient.
    Mysliwietz J; Thierfelder S
    Blood; 1992 Nov; 80(10):2661-7. PubMed ID: 1358260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone hyperacetylation is associated with amelioration of experimental colitis in mice.
    Glauben R; Batra A; Fedke I; Zeitz M; Lehr HA; Leoni F; Mascagni P; Fantuzzi G; Dinarello CA; Siegmund B
    J Immunol; 2006 Apr; 176(8):5015-22. PubMed ID: 16585598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
    Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation.
    Tomita Y; Sachs DH; Khan A; Sykes M
    Transplantation; 1996 Feb; 61(3):469-77. PubMed ID: 8610363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-CD3 treatment facilitates engraftment of full H-2-disparate donor bone marrow cells and subsequent skin allograft tolerance.
    de Vries-van Der Zwan A; Besseling AC; Kievits F; van Twuyver E; de Waal LP
    Transplantation; 1994 Sep; 58(5):610-7. PubMed ID: 7522366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
    Slavin S; Nagler A; Varadi G; Or R
    Exp Hematol; 2000 Jul; 28(7):853-7. PubMed ID: 10907647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
    Reilly CM; Mishra N; Miller JM; Joshi D; Ruiz P; Richon VM; Marks PA; Gilkeson GS
    J Immunol; 2004 Sep; 173(6):4171-8. PubMed ID: 15356168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
    Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.